COVID-19: BioNTech says developed method to detect high-risk variants

The new method can analyse genetic sequencing data of new COVID mutations

Last updated:
File photo: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany.
File photo: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany.
REUTERS

Frankfurt: German COVID-19 vaccine maker BioNTech said it developed a method to quickly determine whether a new virus variant is a cause for concern, collaborating with British artificial intelligence startup InstaDeep Ltd.

In a joint statement on Tuesday, BioNTech and its partner said the new computational method can analyse genetic sequencing data of new coronavirus mutations found in infected people and assesses the risk they pose within days and sometimes within just minutes.

Get Updates on Topics You Choose

By signing up, you agree to our Privacy Policy and Terms of Use.
Up Next